Is ERK activation a good biomarker for estradiol and tamoxifen effects?
Smalley
Keiran S M
KS
Wistar Institute, Philadelphia, Pennsylvania, USA.
Flaherty
Keith T
KT
D018931:Antineoplastic Agents, Hormonal / Q000494:pharmacology* / Q000627:therapeutic use; D015415:Biomarkers / Q000032:analysis / Q000378:metabolism; D019008:Drug Resistance, Neoplasm; D004789:Enzyme Activation; D004958:Estradiol / Q000494:pharmacology* / Q000627:therapeutic use; D048049:Extracellular Signal-Regulated MAP Kinases / Q000032:analysis* / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy / Q000201:enzymology*; D013629:Tamoxifen / Q000494:pharmacology* / Q000627:therapeutic use
D018931:Antineoplastic Agents, Hormonal; D015415:Biomarkers; D013629:Tamoxifen; D004958:Estradiol; D048049:Extracellular Signal-Regulated MAP Kinases